Information Provided By: 
Fly News Breaks for July 14, 2017
ACRX
Jul 14, 2017 | 08:45 EDT
Jefferies analyst Matthew Andrews assumed coverage of AcelRx Pharmaceuticals with a Buy rating and $7 price target. The stock is undervalued given the "potent" oral opioid Dsuvia's promise in medically-supervised acute pain markets, Andrews tells investors in a research note. He sees a high likelihood of approval in the U.S. and Europe late in 2017 or early 2018. The analyst views the stock's risk/reward as favorable with downside to $1.25 on no approvals and upside potential of $12.
News For ACRX From the Last 2 Days
There are no results for your query ACRX
